StudyFinder
Search Results
477 Study Matches
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Sherry Boyett, RN - sherry.boyett@vcuhealth.org
NCT05424003
Inclusion Criteria:
* Male or female age 18-75 years who received LT for any indication (i.e. NASH, hepatitis C, alcohol-induced cirrhosis, autoimmune hepatitis, etc.)
* Liver transplant surgery within 8-24 weeks prior to randomization
* Fasting glucose \> 125 mg/dL or presence of diabetes (HbA1c≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c \>5.7%)
* Ability to provide informed consent
* Discharged from the hospital following LT surgery
* Tolerating diet
* Normal graft function\* (determined by treating hepatologist/surgeon based on clinical status and hepatic panel)
* Stable immunosuppression according the VCU (Virginia Commonwealth University) post-LT protocols \*\* (i.e. calcineurin inhibitors + mycophenolate)
* Eligible female patients will be (1) non-pregnant, evidenced by a negative urine pregnancy test, (2) non-lactating, (3)surgically sterile or post-menopausal, or they will agree to continue to use an accepted method of birth control during the study
Exclusion Criteria:
* BMI≤ 27kg/m2
* GFR (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
* Type 1 autoimmune diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
* History of gastroparesis
* Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2
* History of pancreatitis
* History of active malignancy post- LT with the exception of non-melanoma skin cancers
* History of uncontrolled or unstable diabetic retinopathy or maculopathy
* Acute cellular rejection
* Hepatic artery thrombosis
* Medical non-compliance
* Active treatment with GLP (glucagon-like peptide)-1RA (receptor agonist) or SGLT (sodium-glucose cotransporter)-2 inhibitors at time of screening
* History of hypersensitivity to semaglutide or its excipients
* Women who are nursing, pregnant, or planning to become pregnant during the study, or are not using adequate contraceptive measures DRUG: Semaglutide Pen Injector, DRUG: Placebo
NAFLD
Liver Transplant
Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia (SCIMS Main)
Ashraf Gorgey, MPT, PhD, FACSM, FACRM - Ashraf.Gorgey@va.gov
NCT05423600
Inclusion Criteria:
• A written clearance from the study medical doctor to ensure that the participant is safely able to engage in the study.
• Participants must have a companion that will be able to help him/her throughout the study.
• Greater than 1-year post SCI, neurologic level of C8 or above.
• American Spinal Injury Association Impairment Scale (AIS) scores of B, C, or D indicating presence of an incomplete SCI.
• Visible muscle contraction response to NMES wrist extensors, bilaterally.
• Agreement to use telehealth services for delivery of research exercise training by study staff. Possesses appropriate technology to engage in telehealth including a personal web camera, computer, microphone, speakers, and high-speed broadband internet connection, valid email address (needed to obtain VA issued video conferencing software), and telephone number used to obtain login credentials for the In-Home Video Software - Cisco Jabber Video for Telepresence Software.
• Response of muscle contraction of wrist extensors bilaterally to neuromuscular electrical stimulation.
Exclusion Criteria:
• Unhealed fracture in upper or lower extremities.
• Severe scoliosis, severe upper extremity contractures, or other musculoskeletal issues that would impede participation in a BES + TS intervention or valid evaluation of outcome measures.
• High resting blood pressure greater than 140/80 mmHg.
• Taking anti-coagulants or anti-platelet agents, including aspirin if unable to be off this medication for medical reasons.
• Pregnancy (female participants). A home pregnancy test will be conducted to role out any pregnancy before the study at the McGuire VAMC. The test will be repeated every month during the course of the study.
• Implanted pacemakers and/or implanted defibrillator devices.
• Other exclusion criteria may include the presence of implanted electrical device, cancer, thrombosis, pacemaker, defibrillator, or seizures. Patients who are currently on or receive anti-platelet or anticoagulant medications will be excluded from the trial.
• Any condition that, in the judgment of the principal investigator or medical provider, precludes safe participation in the study.
• Other exclusion criteria at the discretion of the medical team may include:
• Uncontrolled autonomic dysreflexia (AD), refers to episodes of AD that do not respond to medications to ensure stable blood pressure in persons with SCI
• Concurrent severe neurological injuries other than SCI: MS, CP, severe TBI, and stroke.
• Unresolved deep vein thrombosis.
• Psychiatric or cognitive impairments that preclude adherence to the intervention.
• Known cardiac pathology that precludes safe participation.
• Metabolic conditions such as cardiovascular disease, uncontrolled type II diabetes mellitus, uncontrolled hypertension, and those on insulin.
• Presence of pressure sores stage three or greater.
• Presence of a symptomatic urinary tract infection.
• Severe spasticity as assessed by the Modified Ashworth Scale.
• Changing neurologic status due to conditions such as progressive posttraumatic syringomyelia.
PROCEDURE: BES + TS, PROCEDURE: Experimental: BES+sham TS
Tetraplegia/Tetraparesis
Spinal Cord Injury
Children's Bipolar Network Treatment Trial I (CBN)
David J Miklowitz, PhD - dmiklowitz@mednet.ucla.edu
NCT05427123
Inclusion Criteria:
* Youth 9-19 years old
* Youth diagnosed with Bipolar disorder (I, II, Other Specified) or Cyclothymic Disorder by the study team during the diagnostic interview screening
* Youth is able to read and communicate in English to the degree necessary to be able to assent and participate (with help) in their treatment and assessments appropriate for ages 9 and up
* Youth has a caregiver able to participate in ongoing basis in assessment and treatment
* The participating caregiver can reliably read and communicate in English for purposes of study consenting, assessment, and treatment, unless preferred language translation services are regularly available.
Exclusion Criteria:
* Youth has DSM-5 diagnosis of autism spectrum disorder
* Youth has DSM-5 diagnosis of substance or alcohol abuse with impairment within 3 mos.
* Youth has a medical or psychiatric disorder that is life-threatening or requires immediate hospitalization or emergency medical or therapeutic treatment
* Evidence of recent sexual or physical abuse of the youth by legally responsible caregivers
* Evidence of recent intimate partner violence between caregivers responsible for the youth's care OTHER: Medication or psychosocial treatment
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Other Specified Bipolar and Related Disorder, Mood Instability, Child Mental Disorder, Adolescent - Emotional Problem
medication, psychosocial, treatment, longitudinal, naturalistic, assessment
GiST (GiST)
Vences, Karina - venceskm@vcu.edu
Goldman, Myla
NOT REQUIRED
HM20022775
Diseases of Nervous System and Sense Organs (320-389)
Uptake of NCI Research Tested Intervention Program to Increase CRC Screening in Rural Setting
Preston, Michael - prestonm2@vcu.edu
Preston, Michael
16928
HM20019703
Rectum, Colon
Community Outreach and Engagement Key Informant Interviews
Cummings, Yvonne - yvonne.cummings@vcuhealth.org
Sheppard, Vanessa, B.
15900
HM20018062
A Cognitive Task Analysis of Pediatric Hematology/Oncology Faculty
DiazGranados, Deborah - diazgranados@vcu.edu
Helou, Marieka, Ann
15801
HM20017417
CASTOR-2: Identifying Subclinical Cardiotoxicity Following RT for Locally Advanced Lung Cancer (CASTOR-2)
Kontos, Emily - kontosej@vcu.edu
Thomas, Georgia
15564
HM20017432
Lung
Killer Immunoglobulin-Like Receptor Interactions to Optimize Natural Killer Cell Function in SCT
Roberts, Catherine, H. - croberts2@vcu.edu
Toor, Amir, A
15122
HM20016672
Other Hematopoietic
Biomarkers of Malignant and Non-Malignant Pleural Effusion
Narron, Kyle, A - Kyle.Narron@vcuhealth.org
Shojaee, Samira
15081
HM20012669
Any Site
Unpacking Multilevel Drivers of Cardiotoxicity Disparities in Breast Cancer Survivors
Sutton, Arnethea - abrahamal@vcu.edu
Sheppard, Vanessa, B.
16953
HM20019941
Breast
Cognitive Support Technology for Postsecondary Students with Traumatic Brain Injuries
Getzel, Elizabeth, E - lgetzel@vcu.edu
Getzel, Elizabeth, E
17135
HM20019040
External Causes of Injury and Poisoning (800-999)
Prognostic Gene Expression Profiling and Adjuv Therapy in Stage IIB-C & IIIA-B Cutaneous Melanoma
Gnanasigamani Manogaram, Merlin Margaret - gnanasigamam@vcu.edu
Poklepovic, Andrew, S
17390
HM20021149
Melanoma, skin
Feasibility, Acceptability, and Preliminary Effectiveness of the ICAN QUIT Tobacco Program at VCUH
Hunley, Rachel - rachel.hunley@vcuhealth.org
Hayes, Rashelle
17440
HM20020118
Any Site
Assessing Electronic Cigarette Nicotine Flux (Project 2 Flux Study)
ctrrecruit@vcu.edu
Breland, Alison
19170
HM20018580
Any Site
Longitudinal Survey and Behavior Assessment of Experienced E-cigarette Users (P4 @ VCU)
ctrrecruit@vcu.edu
Breland, Alison
19168
HM20018209
Any Site
Salad Bars in the National School Lunch Program
ctrrecruit@vcu.edu
Bean, Melanie, K.
19167
HM20012226
Any Site
Predicting Effects of Tobacco Product Flavor Regs Among Black/African American Menthol Smokers
ctrrecruit@vcu.edu
Cobb, Caroline
19166
HM20022619
Any Site
Effects of E-Cigarette Nicotine Delivery on Abuse Liability in Smokers
ctrrecruit@vcu.edu
Cobb, Caroline
19165
HM20018290
Any Site
Noninvasive Assessment of Esophageal Varices in Patients with Unresectable Hepatocellular Carcinoma
ctrrecruit@vcu.edu
Wedd, Joel
19108
HM20023235
Pt QoL & Social Support after Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemo
Freudenberger, Devon - devon.freudenberger@vcuhealth.org
Trevino, Jose
19045
HM20023396
Soft Tissue
Role of GABA in Motor Symptoms and Neurophysiological Abnormalities in Dystonia
Crump, Elizabeth - crumpeg@vcu.edu
Berman, Brian
18815
HM20021040
Diseases of Nervous System and Sense Organs (320-389)
Cancer Prevention for Virginia Firefighters
ctrrecruit@vcu.edu
Burch, James
18656
HM20022904
Any Site
ECMT? Consortium (ECMT2)
Ghobrial, Silvia - ghobrials@vcu.edu
Randall, Leslie
18243
HM20022876
Other Female Genital, Corpus Uteri
UPBEAT-DIET (UPBEAT_Die)
Bellissimo, Moriah - Moriah.BellissimoMyers@vcuhealth.org
Hundley, W. Gregory
18021
HM20021545
Breast
Women's Treatment Experiences Study (WTES)
ctrrecruit@vcu.edu
Sheppard, Vanessa, B.
17999
HM20020923
Breast
Validation of the BLESS Models for Predicting Survival in Breast or Lung Cancer
Shojaee, Samira - samira.shojaee@vcuhealth.org
Shojaee, Samira
17961
HM20021607
Any Site
Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk
Shetty, Shreya - shettysa@vcu.edu
Burch, James
17947
HM20021857
Rectum, Colon
Longitudinal Cohort Registry of Cancer Survivors
Hong, Susan - susan.hong@vcuhealth.org
Hong, Susan
17880
HM20021510
Anus, Any Site, Bones and Joints, Breast, Brain and Nervous System, Other Hematopoietic, Other Female Genital, Other Endocrine System, Other Digestive Organ, Non-Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Mycosis Fungoides, Multiple Myeloma, Melanoma, skin, Lymphoid Leukemia, Lung, Liver, Lip, Oral Cavity and Pharynx, Leukemia, other, Leukemia, Not Otherwise Specified, Larynx, Kidney, Kaposi's sarcoma, Ill-Defined Sites, Hodgkin's Lymphoma, Eye and Orbit, Esophagus, Corpus Uteri, Colon, Cervix, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Urinary, Urinary Bladder, Thyroid, Stomach, Soft Tissue, Small Intestine, Rectum, Prostate, Pancreas, Ovary, Other Skin